Sarah Hogan

I like meeting new people with creative ideas and building solutions to set them up for success. Startup companies have an infectious optimism, and working with startups fosters my own creativity.

Experience: I advise life sciences and digital health companies in connection with structuring and negotiating intellectual property licenses, strategic collaborations and other complex commercial transactions. The commonality among life sciences and digital health startup founders is their innovative approach to developing solutions for healthcare needs. I help startups in the early days develop a strategy for working with outside partners to further development of these solutions.  

Making connections: One of my favorite things is when I am able to connect clients who have synergies in their business plans. I once invited two of my clients to a conference to speak on a panel together with intent to introduce them because I knew that their businesses were complimentary and they both had similar energy and passion for their work. They immediately hit it off, and two years later signed a partnership together.  

Off the clock: You can find me skiing or running. I also enjoy spending time with my family, walking my dog, and trying out delicious new restaurants. 

Recommendations: I love audiobooks! I recently finished the audiobook, Lessons in Chemistry by Bonnie Garmus, which is an amazing story of a misunderstood, brilliant woman. Her tenacity in pursuing her passion is inspiring – I highly recommend it. I also enjoy podcasts; Freakonomics is one of my favorites for its deep dive into different economics-related issues. 

Recent Matters:

• Arbor Biotechnologies, an early-stage life sciences company focused on genetic medicines, in its strategic partnership with 4D Molecular Therapeutics focused on treating large market diseases; strategic research collaboration agreement with Vertex Pharmaceutical valued at up to $1.2 billion; strategic research collaboration with TCR2 Therapeutics focused on the development of allogeneic TRuC-T cell therapies; and worldwide non-exclusive license agreement with EdiGene to advance Ex Vivo engineered cell therapy programs.
• Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, in its multi-target research collaboration with Pfizer valued at up to $1.35 billion.
• Voyager Therapeutics, a biotechnology company dedicated to advancing neurogenetic medicines, in its strategic collaboration agreement with Neurocrine Biosciences to advance multiple gene therapies for the treatment of neurological diseases; and its strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG, to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA).